Wuhan Healthgen Biotechnology Corp. (SHA:688765)

SHA:688765 Revenue

Wuhan Healthgen Biotechnology had revenue of 9.14M CNY in the quarter ending June 30, 2026, with 43.77% growth. This brings the company's total for the last twelve months to 23.39M, down -3.62% year-over-year. In the year 2024, Wuhan Healthgen Biotechnology had annual revenue of 25.22M with 3.92% growth. That makes Wuhan Healthgen Biotechnology the 41,033rd largest company in the world by revenue and 5,135th in China.

• Revenue (ttm): 23.39M
• Revenue Growth: -3.62%
• P/S Ratio: 463.94
• Revenue / Employee: n/a
• Employees: 215
• Market Cap: 10.85B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Overseas 13.04M 51.7%
• China 12.18M 48.3%

Fiscal year ended Dec 31, 2024 See the full SHA:688765 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	25.22M	952.02K	3.92%
Dec 31, 2023	24.26M	10.86M	81.08%
Dec 31, 2022	13.40M	-12.12M	-47.49%
Dec 31, 2021	25.52M	3.95M	18.33%
Dec 31, 2020	21.57M	11.32M	110.40%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 30, 2026

Data Sources Report a data error